Summary
=======

LV mass by CMR is a powerful predictor of adverse cardiovascular outcomes in patients treated with anthracyclines.

Background
==========

Late gadolinium enhancement (LGE) is a predictor of adverse outcomes in patients. However, limited data exist on the role of LGE, the characteristic CMR findings, and the prognostic variables in patients who develop a cardiomyopathy after treatment with anthracyclines.

Methods
=======

LGE-CMR imaging was performed in patients with stage B and C heart failure after anthracycline-based chemotherapy. We assessed the association between CMR, EKG, echocardiographic, serum, and clinical variables with adverse outcomes (cardiovascular death and admission for heart failure).

Results
=======

We performed a clinically-indicated CMR study on 50 patients (52% male, mean age of 49 ± 16 years, anthracycline dose of 286 ± 89 mg/m2, and ejection fraction of 38 ± 9%) with AC-mediated cardiomyopathy. Patients presented a median of 45 months after chemotherapy and were followed for a median period of 28 months. LGE was an uncommon finding (3 patients, 6%). There was a strong inverse association between anthracycline dose and indexed left ventricular mass by CMR (r = -.75, p \< 0.001, Figure [1](#F1){ref-type="fig"}). In univariate analysis, indexed LV-mass by CMR demonstrated the strongest unadjusted association with adverse events (hazard ratio: 0.75, chi-squared 26.2, p \< 0.001). In a multivariable model, indexed LV-mass demonstrated the strongest association with the primary outcome (Figure [2](#F2){ref-type="fig"}).
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Conclusions
===========

Residual LV-mass measured by CMR is a powerful predictor of subsequent adverse cardiovascular events in patients with anthracycline-induced cardiotoxicity.

Funding
=======

Dr. Neilan is supported by an NIH T32 Training Grant (T32HL09430101A1).
